Invasive pulmonary aspergillosis (IPA) may complicate severe COVID-19 patients The incidence, although is not well confirmed, varies (20-35%) and the already recognized host factors for IPA in immunosuppressed patients are not identified in non-immunocom-promised patients with COVID-19 associated pulmonary aspergil-losis (CAPA) Additionally, clinical characteristics and radiological findings are not specific Given the probable high burden of the co-infection, a screening diagnostic work-up, including serum and BAL galactomannan measurement, fungal cultures of upper and lower respiratory tract samples are considered mandatory in all mechanically ventilated patients with COVID-19 Pneumon 2020, 33(2):1-4 © 2020, Technogramma All rights reserved
Covid-19 associated aspergillosis